Emcure Pharmaceuticals Limited
₹1,868.10+₹4.35 (+0.2%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹29,399 Cr
- P/E
- 67.9x
- EV / EBITDA
- 53.5x
- Revenue
- ₹4,382 Cr
- Net margin
- 4.6%
- ROCE
- 12.5%
Price chart
Technical chartScreen technicals →+39.9% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -3.8%
- 3M
- -2.2%
- 6M
- +11.2%
- 1Y
- +39.9%
- 5Y
- +37.2%
52-week range
Day change +₹4.35 (+0.2%) from ₹1,864 to ₹1,868 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in EMCURE, bought on each weekday since 2024.
AI Summary
Indian StockStrengths1
- Maintains healthy dividend payout of 23.0%
Concerns1
- Low return on equity of 8.3%
Rule-based from financial data. Not advice.
About the company
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular.
Read moreShow less
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.
- Sector
- Healthcare
- Shares outstanding
- 19.0 Cr shares
- ISIN
- INE168P01015
- BSE code
- 544210
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹29,399 Cr
- P/E
- 67.9x
- P/B
- 9.1x
- EV / EBITDA
- 53.5x
- EV / Sales
- 8.7x
- P/S
- 8.4x
- Earnings yield
- 1.5%
- 52-week high
- ₹2,015.75
- 52-week low
- ₹1,318.00
Profitability
- Operating margin
- 12.6%
- Net margin
- 4.6%
- EBITDA margin
- 16.3%
- ROE
- 8.3%
- ROCE
- 12.5%
- ROA
- 3.4%
- Dividend payout
- 23.0%
- Tax rate
- 20.0%
- Other income, % of PBT
- 64.5%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹4,382 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 25.3%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 8.0%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹571 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 2.3%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 96.9%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -1.7%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹585 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 15.8%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹71.0 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 3.1%
Solvency and efficiency
- Current ratio
- 2.39
- Debt / Equity
- 0.82
- Debt / Assets
- 0.34
- Debt / EBITDA
- 2.79
- Interest coverage
- 2.66
- Financial leverage
- 2.46
- CFO / Net profit
- 3.63
- Cash / Market cap
- 7.6%
- Cash per share
- ₹118.60
- Asset turnover
- 0.74
- Fixed asset turnover
- 2.04
- Capital intensity
- 0.49
- Debtor days
- 115 days
- Inventory turnover
- 1.77
- Cash conversion cycle
- 101 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹7 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹3,759 Cr |
| Sales | Operating profit | ₹623 Cr |
| Operating profit | Interest | ₹113 Cr |
| Operating profit | Depreciation | ₹225 Cr |
| Operating profit | Profit before tax | ₹285 Cr |
| Other income | Profit before tax | ₹142 Cr |
| Profit before tax | Tax and other | ₹111 Cr |
| Profit before tax | Net profit | ₹317 Cr |
Revenue and net profit
Revenue grew 25.3% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹3,154 Cr | ₹420 Cr |
| FY2022 | ₹3,387 Cr | ₹447 Cr |
| FY2023 | ₹3,107 Cr | ₹160 Cr |
| FY2024 | ₹3,498 Cr | ₹161 Cr |
| FY2025 | ₹4,382 Cr | ₹317 Cr |
Cash flows
FY2025: ₹558 Cr from operations, ₹120 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹775 Cr | -₹61 Cr |
| FY2022 | ₹428 Cr | ₹34 Cr |
| FY2023 | ₹505 Cr | ₹234 Cr |
| FY2024 | ₹585 Cr | ₹412 Cr |
| FY2025 | ₹558 Cr | ₹120 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹4,382 Cr+25.3%1Y
- Net profit
- ₹317 Cr+96.9%1Y
- Cash from operations
- ₹558 Cr
- Free cash flow
- ₹120 Cr-70.9%1Y
- Revenue CAGR, 5Y
- 8.0%
- EBITDA CAGR, 5Y
- 2.0%
- Net profit CAGR, 5Y
- -1.7%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹4,382 Cr | ₹623 Cr | — | ₹317 Cr | ₹558 Cr | ₹120 Cr | 10.5% | +25.3% | +96.9% |
Monthly returns
Month-by-month returns of EMCURE across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹5,416 Cr |
| Equity capital | ₹189 Cr |
| Reserves | ₹2,835 Cr |
| Borrowings | ₹857 Cr |
| Other liabilities | ₹1,534 Cr |
| Assets | ₹5,416 Cr |
| Fixed assets | ₹1,759 Cr |
| Capital work in progress | ₹99 Cr |
| Investments | ₹678 Cr |
| Other assets | ₹2,880 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
EMCURE trades at 67.9x earnings against a peer median of 52.6x (a 29% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Emcure Pharmaceuticals LimitedEMCUREthis companyP/E ↑ premium | ₹29,399 Cr | 67.9x | 9.1x | 8.3% | 53.5x |
| Ajanta Pharma Ltd.AJANTPHARM | ₹34,058 Cr | 35.8x | 8.3x | 23.6% | 27.3x |
| Global Health LimitedMEDANTA | ₹31,404 Cr | 59.8x | 8.3x | 16.0% | 37.3x |
| Aster DM Healthcare LimitedASTERDM | ₹31,356 Cr | 92.8x | 7.1x | 5.4% | 78.2x |
| J.B. Chemicals & Pharmaceuticals LtJBCHEPHARM | ₹29,217 Cr | 41.5x | 7.9x | 18.8% | 32.1x |
| Gland Pharma LimitedGLAND | ₹28,321 Cr | 24.5x | 2.8x | 11.6% | 17.3x |
| Syngene International LimitedSYNGENE | ₹25,375 Cr | 58.0x | 5.5x | 11.1% | 26.5x |
| Krishna Institute of Medical Sciences LimitedKIMS | ₹24,919 Cr | 87.7x | 10.9x | 12.6% | 65.6x |
| Pine Labs LimitedPINELABS | ₹24,711 Cr | 442.0x | — | -9.1% | 164.0x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
EMCURE since 1 January, against earlier years.
Historical volatility
EMCURE's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 24.0% |
| FY2022 | 23.0% |
| FY2023 | 14.0% |
| FY2024 | 13.0% |
| FY2025 | 14.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹4,382 Cr |
| Costs | |
| Interest | ₹113 Cr |
| Expenses | ₹3,759 Cr |
| Operating profitOperating Profit | ₹623 Cr |
| Other income and charges | |
| Profit before tax | ₹428 Cr |
| Tax | |
| Net profitNet Profit | ₹317 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹5,416 Cr |
| Equity capitalEquity Capital | ₹189 Cr |
| Reserves | ₹2,835 Cr |
| Borrowings | ₹857 Cr |
| Other liabilitiesOther Liabilities | ₹1,534 Cr |
| AssetsTotal Assets | ₹5,416 Cr |
| Fixed assetsFixed Assets | ₹1,759 Cr |
| Capital work in progressCWIP | ₹99 Cr |
| Investments | ₹678 Cr |
| Other assetsOther Assets | ₹2,880 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹558 Cr |
| Investing cash flowCash from Investing Activity | -₹438 Cr |
| Financing cash flowCash from Financing Activity | -₹49 Cr |
| Change in cashNet Cash Flow | ₹71 Cr |
Learn while you research
Academy chapters picked for Emcure Pharmaceuticals Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 67.9, learn when high multiples are justified.6 min read
- 04 Growth Investing25% revenue growth is in the top tier, learn how to value growth.7 min read
- 05 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 06 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read